Bayer Appoints Prof. Dr. Dominik Ruettinger as the New Head of Research and Early Development for Oncology at its Pharmaceuticals Division

The German life sciences enterprise, Bayer, announced Professor Dominik Ruettinger as the new Head of Research and Early Development for Oncology at its Pharmaceuticals Division, beginning 1 October 2021. Dominik has spent 12 years in academia, working in both Germany and the US. He is board-certified in Surgical Oncology and holds a Ph.D. degree in tumor immunology from the University of Munich, where he also served as principal investigator on multiple Phase I-III clinical oncology trials.

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.